12:00 AM
 | 
Oct 24, 2016
 |  BC Extra  |  Clinical News

Partial clinical hold for Aduro's Listeria candidates

Aduro Biotech Inc. (NASDAQ:ADRO) slipped $0.55 to $11.70 on Monday after it said FDA placed a partial clinical hold on trials evaluating candidates developed using the company's Listeria monocytogenes-based immunotherapy construct (LADD) platform. The hold will pause new patient enrollment in the studies, while patients already treated with...

Read the full 230 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >